Guilbot A, et al. - The physicians conducted this observational study to examine the effect of a proprietary supplement containing feverfew (Tanacetum parthenium L.), coenzyme Q10, and magnesium for migraine prophylaxis. They proposed that for the prevention of migraine, the proprietary supplement containing feverfew, coenzyme Q10, and magnesium assessed could be beneficial and safe in adult patients and merited further study.

• General practitioners enrolled adult patients suffering from migraine according to the criteria of the International Headache Society (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse).
• And, after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.

• Compared to baseline phase, supplementation significantly reduced the number of days with migraine headache during the third month of supplementation (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion).
• The reduction was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001).
• After 3 months, the proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68), with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months).
• In this study, the proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety.
• Furthermore, an improvement of quality of life (Qualité de Vie et Migraine questionnaire) was observed.
• As per the outcomes, the combination was well tolerated.